Efficacy and Safety of Short-term Postoperative Anticoagulant Therapy to Prevente Thrombosis in Arterovenous Fistula

Objective. To perform a systematic evaluation of the efficacy and safety of combined treatment of Shenmai injection and chemotherapy for lung cancer. Methods. A literature search for randomized controlled trials (RCTs) describing the treatment of lung cancer by Shenmai injection and chemotherapy or chemotherapy alone was performed using the PubMed, Cochrane Library, China National Knowledge Infrastructure (CNKI), Value In Paper (VIP), China BioMed, and Wanfang databases. The databases were searched for entries published before September 1, 2019. Results. Thirty-seven RCTs, comprising a total of 2808 cases, were included in the present meta-analysis. Of these, 1428 cases were treated by Shenmai injection plus chemotherapy, and 1380 cases were treated only by chemotherapy. The results of meta-analysis showed that the combined treatment (Shenmai injection plus chemotherapy) increased the short-term efficacy of treatment (relative risk [RR] = 1.183, 95% confidence interval [CI] = 1.043–1.343, P < 0.01 ) and improved patients’ quality of life (RR = 1.514, 95%CI = 1.211–1.891, P < 0.01 ) compared with chemotherapy alone. With regard to the adverse effects, the combined treatment markedly reduced the incidence of white blood cell (WBC) reduction (RR = 0.846, 95%CI = 0.760–0.941, P < 0.01 ), platelet reduction (RR = 0.462, 95% CI = 0.330–0.649, P < 0.01 ), and hemoglobin reduction (RR = 0.462, 95% CI = 0.330–0.649, P < 0.01 ) and alleviated drug-induced liver injury (RR = 0.677, 95%CI = 0.463–0.990, P < 0.05 ). However, it did not offer a significant protective effect (RR = 0.725, 95%CI = 0.358–1.468, P < 0.05 ). The effect of the combined treatment on the occurrence of vomiting was considerable (RR = 0.889, 95%CI = 0.794–0.996, P < 0.05 ), and the combined treatment markedly increased the immunity of patients with lung cancer. Conclusion. The combined treatment of Shenmai injection plus chemotherapy enhanced the short-term efficacy of chemotherapy, improved the patient quality of life, alleviated the adverse effects of chemotherapeutics, and increased the patient immunity. These results should be confirmed by large-scale, high-quality RCTs.

Download Full-text

The choice of an oral anticoagulant

Drug and Therapeutics Bulletin ◽

10.1136/dtb.10.7.25 ◽

1972 ◽

Vol 10 (7) ◽

pp. 25-28 ◽

Cited By ~ 1

Keyword(s):

Myocardial Infarction ◽

Atrial Fibrillation ◽

Anticoagulant Therapy ◽

Cerebral Ischaemia ◽

Oral Anticoagulant ◽

Short Term ◽

Prevention And Treatment ◽

Transient Cerebral Ischaemia

Some of the indications for anticoagulant therapy remain controversial, but they are widely used for the prevention and treatment of thrombosis and embolism after surgery1 and after myocardial infarction,2 in patients with atrial fibrillation, and in those with transient cerebral ischaemia.3 This article discusses the drugs available for long-term use. Those suitable for immediate and short-term use, heparin and arvin, will be discussed in the next issue.

Download Full-text

DI-039 Evaluation of the efficacy and safety of short-term boceprevir and telaprevir in the treatment of chronic hepatitis C virus infection

European Journal of Hospital Pharmacy ◽

10.1136/ejhpharm-2013-000436.210 ◽

2014 ◽

Vol 21 (Suppl 1) ◽

pp. A86.1-A86

Author(s):

O Garcia Molina ◽

F Mendoza Otero ◽

MA Fernandez de Palencia Espinosa ◽

MM Galindo Rueda ◽

J Velasco Costa ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C Virus ◽

Hepatitis C ◽

Virus Infection ◽

Chronic Hepatitis C ◽

Efficacy And Safety ◽

Hepatitis C Virus Infection ◽

Short Term ◽

Chronic Hepatitis C Virus

Download Full-text

Hyposensitization with Seven Injections: A Placebo-Controlled, Double-blind Multicenter Study of the Efficacy and Safety of Short-Term Immunotherapy With Molecular-Standardized Grass/Rye Allergen

New Trends in Allergy IV ◽

10.1007/978-3-642-60419-5_61 ◽

1997 ◽

pp. 355-356

Author(s):

H. Wolf ◽

H. P. Zenner ◽

C. Schmitz-Salue

Keyword(s):

Multicenter Study ◽

Efficacy And Safety ◽

Short Term ◽

Double Blind

Download Full-text

THALIDOMIDE FOR PATIENTS WITH THALASSEMIA INTERMEDIA: A RETROSPECTIVE MULTICENTER CLINICAL STUDY

Mediterranean Journal of Hematology and Infectious Diseases ◽

10.4084/mjhid.2020.021 ◽

2020 ◽

Vol 12 (1) ◽

pp. e2020021

Author(s):

Kun Yang ◽

Yi Wu ◽

Yali Zhou ◽

Tianhong Zhou ◽

Li Wang ◽

...

Keyword(s):

Blood Transfusion ◽

Laboratory Data ◽

Drug Discontinuation ◽

Therapeutic Effects ◽

Efficacy And Safety ◽

Thalassemia Intermedia ◽

Short Term ◽

Long Term Follow Up

Objective: This study focused on the efficacy and safety of thalidomide for patients with thalassemia intermedia (TI) in a multicenter trial. Methods：Clinical and laboratory data of 62 patients subjected to thalidomide therapy in four centers were retrospectively analyzed. We evaluated the efficacy and safety of thalidomide in the short-term (three months) and long-term follow-up (12 and 24 months). Response to thalidomide was defined as follows: Main Responder (MaR) showing an increase in Hb level of >2.0 g/dl or removal from blood transfusion and Minor Responder (MiR) achieving elevated hemoglobin (Hb) level of 1.0-2.0 g/dl or ≥50% reduction in blood transfusion frequency. Results：The overall response rate (ORR) of 62 patients with TI was 93.5% (58/62), with MaR and MiR rates accounting for 62.9% (39/62) and 30.6% (19/62) in short-term follow-up and 66.1% (41/62) and 27.4% (17/62) in long-term follow-up, respectively. The clinical response during long-term follow-up was maintained and the Hb level remained stable during the observation period. The response was still observed in patients with dose reduction despite a slight decrease in Hb level. However, Hb decreased rapidly to the baseline level after drug discontinuation. No effect of thalidomide on spleen size in nonsplenectomized patients was evident. Minimal side-effects were documented throughout, except peripheral neurotoxicity in one patient. Nevertheless, the mean serum ferritin (SF) level was significantly increased after treatment. Conclusion: Thalidomide had significant therapeutic effects on patients with TI, and the response was sustained with acceptable short-term and long-term adverse reactions. While these preliminary results support the potential long-term efficacy and safety of thalidomide as a therapeutic agent for TI, several issues need to be addressed before its application in the clinic.

Download Full-text